Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D001772:Blood Cell Count; D001792:Blood Platelets; D002986:Clinical Trials as Topic; D003562:Cytidine / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D014227:Triazines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D014227:Triazines; D003562:Cytidine; D001374:Azacitidine